This study is NOT currently recruiting. 

Description:  The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Eligibility & Criteria 

IRB #: IRB00347627
 
Principal Investigator: Dr. Doris Leung
 
Eligible Age Range: 18-65

Gender:  All

Diagnosis:  Facioscapulohumeral Muscular Dystrophy